Innovative interactive biomembranes for acute wound management

Important results from the project

Colzyx develops a whole new concept in wound management called WOUNDCOM. This product is a so-called bioactive wound dressing to be used after surgery in hospitals. This type of bioactive wound dressing is brand new. Developing this product, we have the following questions: 1) Is WOUNDCOM to be considered as a medical device or is it a new form of drug. The answer to this question will be crucial considering time and cost for future clinical studies that need to be adressed. 2) What price this product may have on the market.

Expected long term effects

Colzyx has used by two reputable internationally recognized external consulting companies. The regulatory report shows that WOUNDCOM is a medical device product and may therefore follow this regulatory path. With regard to the health-economic price analysis, the result became a economical model based on that WOUNDCOM is used for surgery to accelerate healing surgical wounds. This means that the patient may be dismissed from the hospital more quickly than today. This justifies a premium price of WOUNDCOM, which is significantly higher at the nearest comparable competitor´s price.

Approach and implementation

The result of both the regulatory and the health economics work greatly strengthens the WOUNDCOM project. The fact that the product is to be considered a medical device product is of great importance for continued planned regulatory work. The health-economic analysis that shows an anticipated premium price is important for continued business development work, where price is a crucial issue for market penetration as well as for calculating future revenues.